Chemotherapy Compounding Pharmacy Management 
Pharmacy Times
JULY 16, 2025
The findings of the DeLLphi-304 study demonstrated improved OS of tarlatamab compared with single-agent chemotherapy (median OS [mOS], 13.6 The updated definition for HRMM is increasingly important as there is an increased focus on how to improve outcomes for patients with HRMM, functional HRMM, and true extramedullary disease.
Pharmacy Times
JUNE 27, 2025
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 9, 2025
doi:10.1056/NEJMoa1901963 Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. N Engl J Med. 2019;380:2020-2030. Subscribe Now!
Pharmacy Times
JUNE 18, 2025
Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A.
Pharmacy Times
JUNE 11, 2025
Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.
Pharmacy Times
JUNE 17, 2025
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Pharmacy Times
JUNE 20, 2025
I think we’re getting to the point now where hematology and oncology both need services that can manage these types of side effects. Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. It’s really been a partnership.
Expert insights. Personalized for you.
26 
Let's personalize your content